In vitro activity of ceftaroline against a broad spectrum of recent clinical anaerobic isolates

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 421-425

  Snydman, David R ^a,b   Jacobus, Nilda V ^a   McDermott, Laura A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTRIAXONE; CLINDAMYCIN; IMIPENEM; METRONIDAZOLE; MOXIFLOXACIN; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; GRAM NEGATIVE ANAEROBIC BACTERIA; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIA, ANAEROBIC; CEFTRIAXONE; CEPHALOSPORINS; CLINDAMYCIN; IMIPENEM; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; QUINOLINES;

EID: 78650647462     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00868-10     Document Type: Article

References (12)

1. Citron, D. M., K. L. Tyrell, C. V. Merriam, and E. J. C. Goldstein. 2010. In vitro activity of ceftaroline against 623 diverse strains of anaerobic bacteria. Antimicrob. Agents Chemother. 54:1627-1632.
2. Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Finegold, S. M., and W. L. George (ed.). 1989. Anaerobic infections in humans. Academic Press, Inc., San Diego, CA.
4. Ge, Y., D. Biek, G. H. Talbot, and D. F. Sahm. 2008. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:3398-3407.
5. Jousimies-Somer, H. R., P. Summanem, D. M. Citron, E. J. Baron, H. Wexler, and S. M. Finegold. 2002. Wadsworth-KTL anaerobic bacteriology manual, 6th ed. Star Publishing Co., Belmont, CA.
6. Mushtaq, S., M. Warner, Y. Ge, K. Kaniga, and D. M. Livermore. 2007. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60:300-311.
7. Sader, H. S., T. R. Fritschie, K. Kaniga, Y. Ge, and R. N. Jones. 2005. Antimicrobial activity of PPI-0903M, a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother. 49: 3501-3512.
8. Sader, H. S., T. R. Fritschie, and R. N. Jones. 2008. Antimicrobial activities of ceftaroline and ME1036 tested against clinical strains of communityacquired methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52:1153-1155.
9. Snydman, D. R., N. V. Jacobus, L. A. McDermott, et al. 2007. National Survey on the Susceptibility of Bacteroides fragilis Group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob. Agents Chemother. 51:1649-1655.
10. Snydman, D. R., N. V. Jacobus, and L. A. McDermott. 2008. In vitro activities of doripenem against recent clinical anaerobic isolates with emphasis on the Bacteroides fragilis group. Antimicrob. Agents Chemother. 52:4492-4496.
11. Snydman, D. R., N. V. Jacobus, and L. A. McDermott. 2009. In vitro activity of ceftaroline versus a broad spectrum of recent clinical anaerobic isolates, abstr. E-203, p. 496. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
12. Wyeth Pharmaceuticals. 2005. Tygacil package insert. Wyeth Pharmaceuticals, Philadelphia, PA. http://fda.gov/cder/foi/label/2005/0218211b1. pdf